Bibliografía del artículo
1. Marks JB. Advances in obesity treatment: clinical highlights from the NAASO 2003 Annual Meeting. Clin Diab 22:23-26, 2004.
2. Word Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, June 3-5, 1997. Geneva:WHO; 1998.
3. James P. Chair of the London-based International Obesity Task Force (IOTF). Monte Claro, 2003. Call for obesity review as overweight numbers reach 1.7 billion. [citado em 17 Mar 2006]. Disponível em: www.iotf.org/media/iotfmar17.htm.
4. Abate N. Obesity and cardiovascular disease: pathogenic role of the metabolic syndrome and therapeutic implications. Journal of Diabetes and its Complications 14:154-174, 2000.
5. Hill JO, Billington CJ. It's time to start treating obesity. Am J Cardiol 89:969-70, 2002.
6. Gokcel A, Gumurdulu Y, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diab Obes and Metab 4:49-55, 2002.
7. Seidell JC, Kahn HS, Williamson DF, Lissner L, Valdez R. Report from a centers for desease control and prevention workshop on use of adult anthropometry for public health and primary health care. Am J Clin Nutr 73:123-126, 2001.
8. Ellis KJ. Select body composition methods can be used in field studies. Phisiol Rev 80:649-680, 2000.
9. Atkinson RL. Use of drugs in the treatment of obesity. Annu Rev Nutr 17:383-403, 1997.
10. National Institutes of Health/National Heart Lung and Blood Institute, North American Association for the Study of Obesity (NHLBI/NAASO). Practical guide to the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda 2000.
11. Gutiérrez A, Saracíbar G, Casis L, Echevarría E, Rodríguez VM, Macarulla MT, et al. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obes Res 10:532-540, 2002.
12. Leibowitz SF, Weiss GF, Suh J. Medium hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behaviour. Pharmac Biochem Behav 37:735-42, 1990.
13. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Statistics in Medicine 17(14):1623-34, 1998.
14. Stunkard AJMD. Current views on obesity. Am J Med 100(2):230-236, 1996.
15. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 68:899-917, 1998.
16. IDF. International Diabetes Federation [citado em Out 2005]. Disponível em: www.idf.org/webdata.docs/IDF_Metasyndrome_definition.pdf.
17. Rexrode KM, Carey VJ, Hennekens VH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal obesity and coronary heart disease in women. JAMA 280:1843-8, 1998.
18. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 3:211S-216S, 1998.
19. Pedrinola F, Sztejnsznajd C, Lima N, Halpern A, Medeiros-Neto G. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 4(6):549-554, 1996.
20. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefullness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 4(4):391-396, 1996.
21. Duarte AC, Faillace GBD, Wadi MT, Pinheiro RL. Síndrome metabólica: semiologia, bioquímica e prescrição nutricional. Rio de Janeiro (RJ). Axcel Books do Brasil, 2005.
22. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. J Clin Psychiatry 3:22-27, 2001.